#China #Hong Kong #Global Expansion #Sino Biopharmaceutical #SBP Group

Introduction

Sino Biopharmaceutical Limited, a prominent player in China's pharmaceutical industry, has unveiled its new global brand, SBP Group. This strategic move is part of the company's ambition to enhance its international presence and accelerate the development and availability of innovative medications across the globe. SBP is an acronym encapsulating the company’s core mission: Science, Breakthroughs, and Patients.

Embracing Globalization

During its recent provisional results meeting, the announcement of the SBP Group marked a significant milestone in Sino Biopharmaceutical's journey. The new branding symbolizes a thorough evolution from a leading national bio-pharmaceutical entity to a truly innovative global player. The company is positioning itself to expand internationally on multiple fronts, focusing on both product and business globalization.

The overarching vision involves creating a robust global portfolio of innovative assets through rigorous internal R&D as well as strategic acquisitions. By forming global alliances and strategically penetrating key international markets, Sino Biopharmaceutical aims to fulfill its mission of delivering cutting-edge therapies to a broader array of patients worldwide.

Commitment to Innovation

Theresa Tse, the Chairperson of the Board, commented on this significant transition, stating, “2026 marks the first year of implementing our globalization strategy, and we have made substantial progress.” The SBP Group is committed to collaborating with global partners to not only expedite the development of innovative drugs but also introduce state-of-the-art therapies to the Chinese market from abroad.

The company intends to leverage its fully integrated AI-driven R&D platform to inspire scientific advancements aimed at improving human health.

Financial Milestones

To date, the company has successfully executed multiple licensing agreements with multinational corporations, accumulating initial payment amounts that exceed 1 billion USD. The total potential value of these transactions is projected to surpass 7 billion USD. Noteworthy achievements for 2026 include:
1. A licensing agreement with Sanofi for rovadicitinib, a leading dual JAK/ROCK inhibitor, valued up to 1.53 billion USD.
2. An exclusive licensing deal with AstraZeneca regarding TQC3721, an inhaled PDE3/4 inhibitor for COPD, with a potential transaction value of up to 1.9 billion USD.

About SBP Group

Sino Biopharmaceutical Limited, now represented as SBP Group, stands at the forefront of innovation in the pharmaceutical sector in China. The company possesses comprehensive capabilities spanning the entire value chain, including research and development, manufacturing, and commercialization. Its product portfolio features a diverse range of biologics and small molecule drugs, establishing a strong leadership position in four significant therapeutic areas: oncology, hepatic/cardiometabolic diseases, respiratory/autoinflammatory diseases, and surgical/analgesic treatments.

Conclusion

The launch of SBP Group epitomizes Sino Biopharmaceutical's commitment to advancing healthcare through innovation. As it strides into international markets, the company’s strategic positioning and dedication to scientific breakthroughs hold promise for both enhancing patient outcomes globally and reinforcing China’s influence in the global pharmaceutical landscape. The road ahead appears promising as SBP Group heralds a new era of patient-focused innovation in medicine.